GENESUM - a Public-Private Collaboration Between MRC Holland and the LUMC

We are thrilled to announce a new public-private partnership between MRC Holland and the Leiden University Medical Center (LUMC) aimed at co-developing a genetic newborn screening (NBS) assay through GENESUM – a project supported by Health~Holland. 

This assay, leveraging our digitalMLPA technology, will initially target severe combined immunodeficiency (SCID), hemoglobinopathies, and Duchenne muscular dystrophy (DMD), and is designed to improve screening specificity and expand the range of detectable conditions.

Our targeted approach provides a practical and cost-effective alternative that bypasses concerns related to incidental findings with many other next-generation sequencing assays, making genetic screening more accessible and easier to implement in existing labs.

We are proud to contribute to the advancement of newborn screening for a healthier future and look forward to sharing updates from this project in the coming years!

More information about the GENESUM project can be found here.